Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nitric Oxide
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SaNOtize to Evaluate Nitric Oxide Nasal Spray for the Treatment of Sinusitis
Details : Nitric Oxide is a guanylate cyclase activator, its novel nasal spray formulation is being evaluated for the treatment of recurrent acute rhinosinusitis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 13, 2024
Lead Product(s) : Nitric Oxide
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Horizons Ventures
Deal Size : $24.0 million
Deal Type : Series B Financing
Details : NONS is currently sold as a medical device under the brand name VirX™ in Thailand, Hong Kong, and Singapore and as a medical device under the brand name of enovid™ in Indonesia, Israel, and Bahrain.
Brand Name : VirX
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 24, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Horizons Ventures
Deal Size : $24.0 million
Deal Type : Series B Financing
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nitric oxide is a naturally occurring molecule known to have antimicrobial properties, including a direct effect on SARS-CoV-2, the virus that causes COVID-19, and its variants.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 13, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : After confirmed exposure to COVID-19, infection rate in participants (n=625) who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 11, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Glenmark Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 3 trial of Nitric oxide reached primary endpoint and demonstrated a reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 09, 2022
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Glenmark Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Nitric Oxide Nasal Spray has been tested in healthy volunteers and patients as part of UK and Canada clinical trials. Glenmark’s exclusive long-term partnership with SaNOtize to manufacture, market and sell NONS extends.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 02, 2021
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The SaNOtize treatment is based on nitric oxide (NO), a natural nanomolecule produced by the human body with proven anti-microbial properties shown to have a direct effect on SARS-CoV-2, the virus that causes COVID-19.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2021
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment for COVID-19
Details : Patients with a self-administered Nitric Oxide Nasal Spray (NONS) application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2021
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SaNOtize's Covid-Busting Nasal Spray Begins UK Trials January 11th
Details : The SaNOtize Nitric Oxide Nasal Spray (NONS) is designed to kill the virus in the upper airways, preventing it from incubating and spreading to the lungs.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2021
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SaNOtize is going to study its Nitric Oxide Releasing Solution (NORSTM) in a Phase II trial for the prevention and early treatment of COVID-19.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 27, 2020
Lead Product(s) : Nitric Oxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?